Kendle Selects Relsys for Electronic Submissions of Safety Reports
Relsys International, the leading developer of adverse event reporting software for the pharmaceutical industry, announced today it will provide enhanced Electronic Submission Manager (ESM) technology to Kendle through its Argus Safety(TM) software solutions. Argus’ ESM technology will allow Kendle, a leading global clinical research organization (CRO), to expedite the transmission of adverse event reports to international regulatory agencies in support of its biopharmaceutical customers. Installation of the new software is expected to be completed by late summer.
“We’re honored to continue our relationship with an international clinical development leader such as Kendle,” said Dave Bajaj, President and CEO of Relsys. “Kendle was one of the first CROs to license Argus for reporting to regulatory agencies, and we’re gratified our solutions continue to meet their rigorous selection criteria.”
Kendle was looking for an electronic submissions solution that was easy to integrate with its current systems, easy to use and support, and met their budget requirements. “We evaluated the benefits and costs of several electronic submissions solutions and companies, and felt that Relsys offered the solution which best fit our needs,” said Sean Neal, IT manager for Kendle. “We believe the Electronic Submission Manager from Relsys will allow us to accommodate adverse event submission requests by our sponsors, and easily and effectively transmit data to and from our sponsors, business partners and regulatory agencies.”
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is among the world’s leading global clinical research organizations. The company delivers innovative and robust clinical development solutions — from first-in-human studies through market launch and surveillance — to help the world’s biopharmaceutical companies maximize product life cycles and grow market share. With the expertise of our more than 1,700 associates worldwide, Kendle has conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries. Investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street, Cincinnati, OH 45202, or from the company’s Web site at http://www.kendle.com
About Relsys International
Relsys International provides comprehensive adverse event and complaint tracking software and services that help pharmaceutical, biotech and medical device companies ensure ongoing compliance to global regulations. The company, founded in 1987, works in partnership with its customers to develop and deliver innovative solutions to long-term business needs, and to provide critical components to support its clients’ corporate risk management strategies. Argus Safety(TM), the company’s flagship product, is the world’s best selling adverse event reporting software, and is used by more of the leading pharmaceutical companies than any other solution. Relsys is a privately held company, headquartered in Irvine, California. For more information, visit http://www.relsys.net
